Prostate Cancer

Study : Does scalp cooling help prevent hair loss after chemotherapy?

Relevance: High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: Patient undergoing chemotherapy

Hair loss is one of the most recognized and distressing side effects of some chemotherapies. Two studies looked at the use of scalp cooling therapy to help reduce hair loss after chemotherapy for early-stage breast cancer. (5/15/17) 

Update: Based on data from clinical trials, the FDA approved Dignicap scalp cooling device for treatment in patients diagnosed with solid tumors who are receiving chemotherapy. 

Study : Angelina Jolie spoke out on BRCA testing: Did genetic testing increase?

Relevance: Medium

Strength of Science: Medium-Low

View Related Clinical Trials

Most relevant for: People interested in genetic testing for an inherited mutation

Angelina Jolie published an editorial in the New York Times in 2013 about her choice to have a double mastectomy after finding out she was positive for a BRCA1 mutation. Researchers from a recent study claim that her celebrity endorsement of BRCA testing may have missed its target audience (previvors), due to the increase in BRCA testing following publication of the editorial but a decrease in the number of mastectomies performed. However, the study failed to take into account that many women without breast cancer do not pursue mastectomy in the months following genetic testing. (1/4/17)

Study : Rare mutations in PALB2, CHEK2, and ATM: how much do they increase cancer risk?

Relevance: Medium-High

Strength of Science: Medium

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People who tested positive for one of the rare variants in CHEK2, ATM or PALB2 that are covered in this study

As multi-gene panel tests become more common, people are discovering they have mutations in genes that are not understood as well as BRCA. This can make it difficult to give patients accurate assessments of their cancer risk. For example, mutations in PALB2, CHEK2, and ATM are rare, but some specific changes in these genes are even less common. The goal of this international collaboration was to better understand the cancer risks of some very rare PALB2, CHEK2, and ATM mutations. The findings are relevant only to the specific mutations covered in this paper and do not apply to all people with mutations in PALB2, CHEK2, or ATM. (9/27/16)

Article : A cancer patient’s tumor is genetically profiled—how does that info help treatment?

Relevance: Medium

Quality of Writing: High

Most relevant for: People diagnosed with advanced cancer

Jessica Wapner's Scientific American article explores the difficulties of making the vast amount of information acquired from tumor gene tests useful to patients and physicians. (9/20/16). Update: THIS INFORMATION HAS BEEN UPDATED. In late 2017, the FDA approved two separate tumor profiling tests to help guide treatment choices. The FoundationOne CDx (F1CDx) genomic test has been approved to test for 15 different targeted therapies used to treat five types of cancer, including ovarian, colorectal, lung, breast and melanoma. The FDA also approved the MSK-IMPACT and developed for use by Memorial Sloan Kettering Cancer Center (MSKCC) to scan tumor samples for 468 different cancer-associated mutations or alterations.

Study : Financial burden affects quality of life of cancer survivors

Relevance: Medium-High

Strength of Science: Medium-High

View Related Clinical Trials

Most relevant for: People diagnosed with cancer

Cancer-related financial burden can keep survivors from getting the care that they need, yet how this burden affects mental and physical health is still unknown. A study found that almost one-third of cancer survivors report having financial burden; those most likely to be affected were under age 65, female, members of racial or ethnic minority groups, and people who lack access to adequate insurance. (5/17/16)

Study : Factors that affect the ability to work in people with metastatic cancer

Relevance: Medium-High

Strength of Science: Medium-High

View Related Clinical Trials

Most relevant for: People living with metastatic cancer

Some patients who live with metastatic cancer either want or need to continue working while coping with symptoms of their disease and treatment. A recent study that looked at over 600 people with metastatic breast, prostate, colon, or lung cancer found that about one-third of them continue working full or part time. People most likely to continue working were those undergoing hormonal treatment and those with less severe symptoms or side effects from treatment. (4/12/16)

Article : New York Times report demonstrates need for genetic counseling, but doesn’t give the whole story

Relevance: Medium

Quality of Writing: Medium-Low

View Related Clinical Trials

Most relevant for: People diagnosed with breast cancer

A New York Times report discussed how genetic testing could provide “grim data” without guidance for patients. While this is a valid concern, this report does not sufficiently emphasize certain important issues regarding genetic testing, particularly the need for genetic counseling by a health care provider with expertise in genetics before and after genetic testing. (4/5/16)

Study : What are the genetics underlying 12 different cancer types?

Relevance: Medium

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People diagnosed with cancer

As gene sequencing has become more affordable, researchers and health care providers are now looking for mutations in many genes beyond BRCA1, BRCA2 and others that are associated with known hereditary cancer syndromes. By sequencing thousands of genes rather than just one or two, researchers can better understand which inherited mutations affect cancer risk. In this study, researchers sequenced thousands of genes in patients with one of 12 cancers, including breast, and catalogued which gene mutations are most commonly found in each cancer. (03/01/16)

Study : How many children with cancer have mutations in genes that increase cancer risk?

Relevance: Medium

Strength of Science: Medium-High

Research Timeline: Human Research

Most relevant for: Survivors of childhood cancer and people with a family history of relatives diagnosed with childhood cancers

Many genes are associated with increased cancer risk in adults, but it is unclear how common these mutations are in children with cancer. This study found that about 9% of children with cancer carry mutations in a gene that is known to increase cancer risk. Over half of the mutations were in the TP53 gene, which is associated with increased cancer risk at a young age and increased risk of breast cancer in adults. (12/15/2015)

Study : Do antioxidants encourage the spread of cancer cells?

Relevance: Low

Strength of Science: Medium

Research Timeline: Animal Studies

View Related Clinical Trials

Most relevant for: The clinical relevance of this study for people is not clear

Scientists do not yet know why some cancers spread to other parts of the body (a process called metastasis). A study in mice suggested that high doses of some antioxidants (chemicals that can protect cells from damage) might actually make it easier for cancer cells to spread. (12/01/2015)